The article discusses the potential impact of renin–angiotensin–aldosterone system (RAAS) inhibitors on patients with Covid-19. The authors highlight the interaction between SARS-CoV-2 and the RAAS through angiotensin-converting enzyme 2 (ACE2), which is a receptor for both viruses. There are concerns about the use of RAAS inhibitors, such as ACE inhibitors and angiotensin-receptor blockers (ARBs), which may alter ACE2 levels and activity, potentially affecting disease severity. However, the data in humans are limited to support or refute these hypotheses. The authors propose that ACE2 may be beneficial rather than harmful in patients with lung injury and raise concerns that withdrawing RAAS inhibitors could be harmful in high-risk patients with known or suspected Covid-19. They emphasize the established benefits of RAAS inhibitors in protecting the kidney and myocardium and recommend continuing these treatments in stable patients at risk for, being evaluated for, or having Covid-19. The article also reviews the prevalence of hypertension among patients with Covid-19 and the potential role of coexisting conditions in severe illness.The article discusses the potential impact of renin–angiotensin–aldosterone system (RAAS) inhibitors on patients with Covid-19. The authors highlight the interaction between SARS-CoV-2 and the RAAS through angiotensin-converting enzyme 2 (ACE2), which is a receptor for both viruses. There are concerns about the use of RAAS inhibitors, such as ACE inhibitors and angiotensin-receptor blockers (ARBs), which may alter ACE2 levels and activity, potentially affecting disease severity. However, the data in humans are limited to support or refute these hypotheses. The authors propose that ACE2 may be beneficial rather than harmful in patients with lung injury and raise concerns that withdrawing RAAS inhibitors could be harmful in high-risk patients with known or suspected Covid-19. They emphasize the established benefits of RAAS inhibitors in protecting the kidney and myocardium and recommend continuing these treatments in stable patients at risk for, being evaluated for, or having Covid-19. The article also reviews the prevalence of hypertension among patients with Covid-19 and the potential role of coexisting conditions in severe illness.